Next Issue
Volume 10, 03
Previous Issue
Volume 10, 01
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.4
Journals
Cardiovascular Medicine
Volume 10
Issue 2
cardiovascmed-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 10, Issue 2 (02 2007) – 4 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
12 pages, 282 KB  
Editorial
Lercanidipin – eine Bereicherung für die Behandlung der arteriellen Hypertonie?
by Rolf P. Engelberger, François Feihl and Bernard Waeber
Cardiovasc. Med. 2007, 10(2), 64; https://doi.org/10.4414/cvm.2007.01231 - 23 Feb 2007
Viewed by 14
Abstract
Calcium-channel blockers (CCB) are one of the main therapeutic options for the treatment of hypertension. Within the CCBs, the subgroup of dihydropyridines (DHP) underwent a particularly rapid evolution. A member of the last generation with an improved pharmacokinetic profile and a higher vascular [...] Read more.
Calcium-channel blockers (CCB) are one of the main therapeutic options for the treatment of hypertension. Within the CCBs, the subgroup of dihydropyridines (DHP) underwent a particularly rapid evolution. A member of the last generation with an improved pharmacokinetic profile and a higher vascular selectivity is lercanidipine. As a result of its long receptor half-life, once-daily dosing produces a sustained blood pressure lowering over 24 hours. The gradual onset of action prevents the occurrence of reflex tachycardia. The antihypertensive action is equivalent to other CCBs or agents from other antihypertensive drug classes. In several clinical trials, lercanidipine has been successfully used in combination with other antihypertensive drugs or as addon therapies. When coadministered with betaadrenoceptor blocking drugs, bioavailability of lercanidipine is decreased and therefore an adjustment in the dosage of the latter may be necessary. It is metabolically neutral and one of its major advantages is the lower incidence of ankle oedema. This has a positive impact on therapeutic compliance, a major topic in the treatment of hypertension. Lercanidipine showed in animal and some clinical studies renal and cardiovascular protective effects, unrelated to its antihypertensive activity. In summary, lercanidipine is characterised by a good efficacy and tolerability profile as well as by a large field of applications by reason of its beneficial pharmacodynamic properties. Full article
Article
Lercanidipin – eine Bereicherung für die Behandlung der arteriellen Hypertonie?
by Rolf P. Engelberger, François Feihl and Bernard Waeber
Cardiovasc. Med. 2007, 10(2), 64; https://doi.org/10.4414/cvm.2007.01230 - 23 Feb 2007
Abstract
Calcium-channel blockers (CCB) are one of the main therapeutic options for the treatment of hypertension. Within the CCBs, the subgroup of dihydropyridines (DHP) underwent a particularly rapid evolution. A member of the last generation with an improved pharmacokinetic profile and a higher vascular [...] Read more.
Calcium-channel blockers (CCB) are one of the main therapeutic options for the treatment of hypertension. Within the CCBs, the subgroup of dihydropyridines (DHP) underwent a particularly rapid evolution. A member of the last generation with an improved pharmacokinetic profile and a higher vascular selectivity is lercanidipine. As a result of its long receptor half-life, once-daily dosing produces a sustained blood pressure lowering over 24 hours. The gradual onset of action prevents the occurrence of reflex tachycardia. The antihypertensive action is equivalent to other CCBs or agents from other antihypertensive drug classes. In several clinical trials, lercanidipine has been successfully used in combination with other antihypertensive drugs or as addon therapies. When coadministered with betaadrenoceptor blocking drugs, bioavailability of lercanidipine is decreased and therefore an adjustment in the dosage of the latter may be necessary. It is metabolically neutral and one of its major advantages is the lower incidence of ankle oedema. This has a positive impact on therapeutic compliance, a major topic in the treatment of hypertension. Lercanidipine showed in animal and some clinical studies renal and cardiovascular protective effects, unrelated to its antihypertensive activity. In summary, lercanidipine is characterised by a good efficacy and tolerability profile as well as by a large field of applications by reason of its beneficial pharmacodynamic properties. Full article
Editorial
Lercanidipin – eine Bereicherung für die Behandlung der arteriellen Hypertonie?
by Rolf P. Engelberger, François Feihl and Bernard Waeber
Cardiovasc. Med. 2007, 10(2), 64; https://doi.org/10.4414/cvm.2007.01229 - 23 Feb 2007
Abstract
Calcium-channel blockers (CCB) are one of the main therapeutic options for the treatment of hypertension. Within the CCBs, the subgroup of dihydropyridines (DHP) underwent a particularly rapid evolution. A member of the last generation with an improved pharmacokinetic profile and a higher vascular [...] Read more.
Calcium-channel blockers (CCB) are one of the main therapeutic options for the treatment of hypertension. Within the CCBs, the subgroup of dihydropyridines (DHP) underwent a particularly rapid evolution. A member of the last generation with an improved pharmacokinetic profile and a higher vascular selectivity is lercanidipine. As a result of its long receptor half-life, once-daily dosing produces a sustained blood pressure lowering over 24 hours. The gradual onset of action prevents the occurrence of reflex tachycardia. The antihypertensive action is equivalent to other CCBs or agents from other antihypertensive drug classes. In several clinical trials, lercanidipine has been successfully used in combination with other antihypertensive drugs or as addon therapies. When coadministered with betaadrenoceptor blocking drugs, bioavailability of lercanidipine is decreased and therefore an adjustment in the dosage of the latter may be necessary. It is metabolically neutral and one of its major advantages is the lower incidence of ankle oedema. This has a positive impact on therapeutic compliance, a major topic in the treatment of hypertension. Lercanidipine showed in animal and some clinical studies renal and cardiovascular protective effects, unrelated to its antihypertensive activity. In summary, lercanidipine is characterised by a good efficacy and tolerability profile as well as by a large field of applications by reason of its beneficial pharmacodynamic properties. Full article
5 pages, 264 KB  
Article
Vorteile des Minimalen Extrakorporellen Kreislaufs in der Koronarchirurgie
by Franz F. Immer, Christoph Häusler, Sara Valerio, Erich Gygax, Concettina Receputo, Beat Kipfer, Hendrik Tevaearai and Thierry Carrel
Cardiovasc. Med. 2007, 10(2), 59; https://doi.org/10.4414/cvm.2007.01227 - 23 Feb 2007
Viewed by 4
Abstract
Objective: Minimal extracorporeal circulation (MECC) is a new perfusion technology, which includes a centrifugal pump and an optoelectrical suction system. The main advantage consists in a significant reduction of the priming volume. Aim of the present study was to analyse if MECC has [...] Read more.
Objective: Minimal extracorporeal circulation (MECC) is a new perfusion technology, which includes a centrifugal pump and an optoelectrical suction system. The main advantage consists in a significant reduction of the priming volume. Aim of the present study was to analyse if MECC has a positive effect in term of reduction of the activation of inflammatory markers and on the incidence of postoperative atrial fibrillation (AF) in comparison to conventional cardiopulmonary bypass (CPB). Methods: Two collectives have been studied: 30 patients scheduled for isolated coronary artery bypass graft (CABG) surgery were randomised to either receive MECC or CPB. Activation of inflammatory markers (IL-6, SC5-b9, Human Lactoferrin) was analysed. In a second collective 86 patients were analysed to evaluate the incidence of AF: 41 patients (47.7%) with CPB and 45 patients (52.3%) with MECC. Patients’ characteristics were similar in both groups. In-hospital outcome was assessed. Results: Inflammatory markers were significant lower in the MECC-group early post operative. AF was documented in 16 patients (39.0%) of the CPB and in 5 patients (11.1%) of the MECC group (p < 0.05). Postoperative the increase of weight was less pronounced in the MECC group (2.9 ± 2.4% vs 4.4 ± 2.6%; p < 0.05). Antiarrhythmic medication was similar in both groups and administered in 95.1% of the patients in the CPB and in 93.3% in the MECC group (p = ns). No differences were found in serum potassium between the two groups (p = ns). Conclusion: MECC is an established and safe perfusion technique. Activation of inflammatory markers is less pronounced in MECC than in CPB patients. The reduction of the priming volume leads to a less pronounced volume shift in the early postoperative period and reduces the incidence of postoperative AF, compared to patients operated with CPB.
Full article
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Previous Issue
Next Issue
Back to TopTop